BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 30140882)

  • 21. Cervical Cancer Screening: Comparison of Conventional Pap Smear Test, Liquid-Based Cytology, and Human Papillomavirus Testing as Stand-alone or Cotesting Strategies.
    Liang LA; Einzmann T; Franzen A; Schwarzer K; Schauberger G; Schriefer D; Radde K; Zeissig SR; Ikenberg H; Meijer CJLM; Kirkpatrick CJ; Kölbl H; Blettner M; Klug SJ
    Cancer Epidemiol Biomarkers Prev; 2021 Mar; 30(3):474-484. PubMed ID: 33187968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force.
    Meza R; Jeon J; Toumazis I; Ten Haaf K; Cao P; Bastani M; Han SS; Blom EF; Jonas DE; Feuer EJ; Plevritis SK; de Koning HJ; Kong CY
    JAMA; 2021 Mar; 325(10):988-997. PubMed ID: 33687469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy.
    Dijkstra MG; van Niekerk D; Rijkaart DC; van Kemenade FJ; Heideman DA; Snijders PJ; Meijer CJ; Berkhof J
    Cancer Epidemiol Biomarkers Prev; 2014 Jan; 23(1):55-63. PubMed ID: 23733907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic accuracy of high-risk HPV DNA genotyping for primary cervical cancer screening and triage of HPV-positive women, compared to cytology: preliminary results of the PIPAVIR study.
    Chatzistamatiou K; Moysiadis T; Angelis E; Kaufmann A; Skenderi A; Jansen-Duerr P; Lekka I; Kilintzis V; Angelidou S; Katsiki E; Hagemann I; Tsertanidou A; Koch I; Boecher O; Soutschek E; Maglaveras N; Agorastos T
    Arch Gynecol Obstet; 2017 May; 295(5):1247-1257. PubMed ID: 28337594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Colorectal Cancer Screening: An Updated Modeling Study for the US Preventive Services Task Force.
    Knudsen AB; Rutter CM; Peterse EFP; Lietz AP; Seguin CL; Meester RGS; Perdue LA; Lin JS; Siegel RL; Doria-Rose VP; Feuer EJ; Zauber AG; Kuntz KM; Lansdorp-Vogelaar I
    JAMA; 2021 May; 325(19):1998-2011. PubMed ID: 34003219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is the HPV-test more cost-effective than cytology in cervical cancer screening? An economic analysis from a middle-income country.
    Vale DB; Silva MT; Discacciati MG; Polegatto I; Teixeira JC; Zeferino LC
    PLoS One; 2021; 16(5):e0251688. PubMed ID: 33989331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling Cervical Cancer Screening Strategies With Varying Levels of Human Papillomavirus Vaccination.
    Grimes DR; Corry EMA; Malagón T; O'Riain C; Franco EL; Brennan DJ
    JAMA Netw Open; 2021 Jun; 4(6):e2115321. PubMed ID: 34190993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical follow-up practices after cervical cancer screening by co-testing: A population-based study of adherence to U.S. guideline recommendations.
    Perkins RB; Adcock R; Benard V; Cuzick J; Waxman A; Howe J; Melkonian S; Gonzales J; Wiggins C; Wheeler CM;
    Prev Med; 2021 Dec; 153():106770. PubMed ID: 34416221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Choosing wisely: a model-based analysis evaluating the trade-offs in cancer benefit and diagnostic referrals among alternative HPV testing strategies in Norway.
    Burger EA; Pedersen K; Sy S; Kristiansen IS; Kim JJ
    Br J Cancer; 2017 Sep; 117(6):783-790. PubMed ID: 28772279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and Associated Factors of Abnormal Cervical Cytology and HighRisk HPV DNA among Bangkok Metropolitan Women.
    Tangjitgamol S; Kantathavorn N; Kittisiam T; Chaowawanit W; Phoolcharoen N; Manusirivithaya S; Khunnarong J; Srijaipracharoen S; Saeloo S; Krongthong W; Supawattanabodee B; Thavaramara T; Pataradool K
    Asian Pac J Cancer Prev; 2016; 17(7):3147-53. PubMed ID: 27509943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reflex cytology for triage of high-risk human papillomavirus positive self-sampled material in cervical cancer screening: a prospective cohort study.
    Loopik DL; Melchers W; Vedder J; van den Brule A; Massuger L; Bekkers R; Siebers AG
    BJOG; 2020 Dec; 127(13):1656-1663. PubMed ID: 32506627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effectiveness of HPV16 and HPV18 genotyping and cytology with different thresholds for the triage of human papillomavirus-based screening on self-collected samples.
    Song F; Du H; Wang C; Huang X; Wu R;
    PLoS One; 2020; 15(6):e0234518. PubMed ID: 32525936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.
    Huh WK; Ault KA; Chelmow D; Davey DD; Goulart RA; Garcia FA; Kinney WK; Massad LS; Mayeaux EJ; Saslow D; Schiffman M; Wentzensen N; Lawson HW; Einstein MH
    J Low Genit Tract Dis; 2015 Apr; 19(2):91-6. PubMed ID: 25574659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting.
    Kotaniemi-Talonen L; Nieminen P; Anttila A; Hakama M
    Br J Cancer; 2005 Oct; 93(8):862-7. PubMed ID: 16189520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epstein-Barr Virus, High-Risk Human Papillomavirus and Abnormal Cervical Cytology in a Prospective Cohort of African Female Sex Workers.
    Cameron JE; Rositch AF; Vielot NA; Mugo NR; Kwatampora JKL; Waweru W; Gilliland AE; Hagensee ME; Smith JS
    Sex Transm Dis; 2018 Oct; 45(10):666-672. PubMed ID: 29664764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Collaborative Modeling to Compare Different Breast Cancer Screening Strategies: A Decision Analysis for the US Preventive Services Task Force.
    Trentham-Dietz A; Chapman CH; Jayasekera J; Lowry KP; Heckman-Stoddard BM; Hampton JM; Caswell-Jin JL; Gangnon RE; Lu Y; Huang H; Stein S; Sun L; Gil Quessep EJ; Yang Y; Lu Y; Song J; Muñoz DF; Li Y; Kurian AW; Kerlikowske K; O'Meara ES; Sprague BL; Tosteson ANA; Feuer EJ; Berry D; Plevritis SK; Huang X; de Koning HJ; van Ravesteyn NT; Lee SJ; Alagoz O; Schechter CB; Stout NK; Miglioretti DL; Mandelblatt JS
    JAMA; 2024 Jun; 331(22):1947-1960. PubMed ID: 38687505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women.
    Bulkmans NW; Rozendaal L; Snijders PJ; Voorhorst FJ; Boeke AJ; Zandwijken GR; van Kemenade FJ; Verheijen RH; v Groningen K; Boon ME; Keuning HJ; van Ballegooijen M; van den Brule AJ; Meijer CJ
    Int J Cancer; 2004 May; 110(1):94-101. PubMed ID: 15054873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience.
    Veijalainen O; Kares S; Kujala P; Vuento R; Osuala V; Tirkkonen M; Luukkaala T; Kholová I; Mäenpää J
    Cytopathology; 2019 Mar; 30(2):150-156. PubMed ID: 30421573
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.